A $150 million combined valuation, a $30 million concurrent private placement, and a CCL24-blocking antibody that nobody was talking about in rheumatoid arthritis six months ago: the Chemomab-Scipher merger is a bet that patient selection, not molecule novelty, is where RA drug development has been breaking down. Chemomab’s nebokitug already generated Phase 2 safety and biomarker data in another indication. Scipher brings something rarer, a commercially live precision medicine business anchored by PrismRA, which received Medicare coverage through a Local Coverage Determination in September 2023, making it the only molecular signature test that CMS has approved for predicting RA treatment response. That reimbursement footprint is not decorative. It gives the combined company a live enrollment filter for a Phase 2 trial that plans to use PrismRA to identify patients biologically likely to respond to nebokitug before they ever receive a dose.
The strategic logic here is distinct from typical reverse-merger opportunism. Scipher’s AI Network Medicine platform independently ranked CCL24 as the top clinical-stage efficacy target in RA, and that finding arrived before the deal terms were set, lending the target selection at least some independence from deal-making incentive. Nebokitug’s dual mechanism, blocking both inflammation and fibrosis through CCL24, addresses a dimension of RA pathology that JAK inhibitors, the last genuinely novel mechanistic class approved for RA, do not touch. The RA market sits at roughly $24 billion, and the source data confirms no new novel mechanism has received FDA approval in RA since 2012, with no new branded approvals at all since 2019. That gap creates real commercial runway for a differentiated mechanism, but only if the Phase 2 reads cleanly.
The ownership split tells the story of who holds leverage. Pre-merger Scipher equity holders take approximately 68% of the combined company on a fully diluted basis, with Chemomab holders receiving around 32% plus contingent value rights tied to nebokitug milestones. Northpond Ventures leads the financing syndicate, with Khosla Ventures, Blue Owl Healthcare Opportunities, and Neuberger-managed funds participating. That roster signals institutional confidence in Scipher’s platform economics, not just the clinical asset. The combined entity will operate under the Scipher Medicine Corporation name and trade on Nasdaq as SCIP, with Reginald Seeto as CEO and Adi Mor moving to the board.
Cash runway extends into H2 2028, and the Phase 2 topline readout is expected in H1 2028, a tight but deliberately sequenced overlap. The single number to track between now and that readout is enrollment rate in the precision-selected cohort: if PrismRA screens out a large proportion of candidates as unlikely responders, the trial shrinks, costs compress, and the signal-to-noise ratio improves. If the test fails to differentiate enrollment at scale, the entire precision premise unravels before the primary endpoint is ever reached.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
